Abstract: Described are compounds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is S02; R1 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y=SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g.

Abstract: 1

Abstract: The disclosure relates to quinoxaline derivates of Formula I wherein R1, R4, R5, R6, R7 and R8 are defined in the disclosure, as well as their production and use in medicinal agents.

Abstract: Quinoxalinedione derivatives ##STR1## as well as their production and use in pharmaceutical agents are described.

Abstract: Quinoxalinedione derivatives of formula (I) ##STR1## are described, and their use in pharmaceutical agents.

Abstract: Compounds of formula I ##STR1## are described, as well as the process for their production and their use in pharmaceutical agents.

Abstract: The disclosure relates to quinoxaline derivatives of Formula I ##STR1## wherein R.sup.1, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined in the disclosure, as well as their production and use in medicinal agents.

Abstract: 5- or 6-substituted .beta.-carboline-3-carboxylic acid esters of Formula I ##STR1## wherein R.sup.1 is hydrogen, nitrilo, halogen, lower alkyl or lower alkoxy, andR.sup.3 is a branched C.sub.3-6 alkyl group which is optionally substituted by halogen, or a C.sub.3-6 cycloalkyl group which is optionally methyl-substituted, are valuable pharmaceuticals.

Abstract: Hetaryloxy-.beta.-carbolines of formula I ##STR1## in which R.sup.A means a triazine or benzocondensed hetaryl radical with 1-2 nitrogen atoms optionally substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 or a 5- or 6-membered hetaryl radical with 1-2 nitrogen atoms substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1are useful pharmaceutical agents.

Abstract: Compounds of formula I are described ##STR1## in which R.sup.3 represents a C.sub.6-12 -aryl or hetaryl radical, optionally substituted singly or multiply with C.sub.1-4 -alkyl, C.sub.3-7 -cycloalkyl, halogen, C.sub.1-4 -alkoxy-C.sub.1-2 -alkyl, phenyl or amino, the process for their production and their use in pharmaceutical agents.

Abstract: .beta.-carbolines of formula I are described ##STR1## in which R.sup.A is a C.sub.6-12 aryl hetaryl as defined herein, that can be substituted singly to multiply with halogen, C.sub.1-4 -alkoxy, C.sub.1-4 -alkyl or amino,X is --(CH.sub.2).sub.n -- or --C.tbd.C--,for use as pharmaceutical agents.

Abstract: 5- or 6-substituted .beta.-carboline-3-carboxylic acid esters of Formula I ##STR1## wherein R.sup.1 is hydrogen, nitrilo, halogen, lower alkyl or lower alkoxy, andR.sup.3 is a branched C.sub.3-6 alkyl group which is optionally substituted by halogen, or a C.sub.3-6 cycloalkyl group which is optionally methyl-substituted, are valuable pharmaceuticals.

Abstract: .beta.-carboline-3-hydroxyalkylcarboxylic acid ester derivatives of formula I ##STR1## in which R.sup.A, n, R.sup.4 and R.sup.3, have the meaning indicated in the claims, as well as their production and their use in pharmaceutical agents are described.

Abstract: Hetaryloxy-.beta.-carbolines of formula I ##STR1## in which R.sup.A means a benzocondensed hetaryl radical with 1-2 nitrogen atoms optionally substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 or a 5- or 6-membered hetaryl radical with 1-2 nitrogen atoms substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 are useful pharmaceutical agents.

Abstract: Compounds of formula I ##STR1## in which R.sup.A, B (which is CR.sup.4) and R.sup.3 and have the meaning indicated in the application, as well as their production and their use in pharmaceutical agents, are described.

Abstract: Heteroaryloxy-.beta.-carboline derivatives of general Formula I ##STR1## wherein R.sup.1 is an optionally substituted heteroaryl residue,R.sup.2 is hydrogen, lower alkyl or lower alkoxyalkyl,X is a COOR.sup.3 -group wherein R.sup.3 means H or lower alkyl, or represents a CONR.sup.4 R.sup.5 -group wherein R.sup.4 and R.sup.5 mean respectively hydrogen or lower alkyl, R.sup.4 and R.sup.5 being capable of forming, together with the nitrogen atom, a 5- to 6-membered heterocycle, or means an oxadiazolyl residue of the formula ##STR2## wherein R.sup.6 means hydrogen, lower alkyl or cycloalkyl, are valuable pharmaceuticals.

Abstract: Imidazole derivatives of general formula I ##STR1## wherein R.sup.1 represents hydrogen or halogen in the o-, m- or p-position, and the halogen can occur once or repeatedly in the phenyl radical,R.sup.4 represents ##STR2## with R.sup.6 and R.sup.9 representing hydrogen or a straight or branched alkyl group with 1 to 6 carbon atoms, R.sup.7 and R.sup.8 are the same or different and represent hydrogen or a straight or branched alkyl group with 1 to 6 carbon atoms or R.sup.7 and R.sup.8 together with the nitrogen atom represent a saturated heterocyclic five-membered or six-membered ring optionally containing another heteroatom, andR.sup.5 represents hydrogen, an alkyl group with 1 to 6 carbon atoms or an alkoxyalkyl group with 1 to 6 carbon atoms, which are suitable as psychopharmaceuticals, are described.

Abstract: A process is disclosed for the preparation of 4-alkoxyalkyl .beta.-carboline derivatives of general Formula I ##STR1## wherein R.sup.1 is hydrogen or methyl,R.sup.2 is an optionally substituted aliphatic hydrocarbon residue,R.sup.3 is lower alkyl, andR.sup.A is hydrogen, halogen, COOR.sup.4 or OR.sup.5, R.sup.4 meaning lower alkyl and R.sup.5 meaning hydrogen, lower alkyl, cycloalkyl, or optionally substituted pheny,by reaction of a compound of Formula II in the presence of AgBF.sub.4 with an alcohol of the formula R.sup.2 OH wherein R.sup.2 has the meanings given above.

Abstract: Phenoxy-substituted beta-carbolines of the formula I ##STR1## X is COOR.sup.3, CONHC.sub.1-3 -alkyl or oxadiazolyl of the formula ##STR2## R.sup.2 is H, lower alkyl or cycloalkyl, R.sup.3 is lower alkyl,R.sup.4 is hydrogen, lower alkyl or lower alkoxyalkyl,R.sup.1 is hydrogen, halogen, lower alkyl, lower alkoxy, acyl, phenyl, C.sub.2-5 alkylenedioxy, trifluoromethyl, nitrilo, nitro, lower alkoxycarbonyl, azido, SO.sub.2 R.sup.6, SO.sub.2 NR.sup.7 R.sup.8, or NR.sup.9 R.sup.10,R.sup.6 is lower alkyl,R.sup.7 and R.sup.8 independently are lower alkyl or together with the nitrogen atom form a hetero ring,R.sup.9 and R.sup.10 independently are hydrogen, lower alkyl, acyl or together with the nitrogen atom form a hetero ring system,with the proviso that X is not COOEt, if ##STR3## is 5-phenoxy and R.sup.4 is methyl or ##STR4## is 6-(4-methoxyphenoxy) and R.sup.4 is methoxymethyl have valuable pharmacological properties.

Abstract: .beta.-Carbolines of general Formula I ##STR1## wherein Y represents the residue ##STR2## and R.sup.a and R.sup.b, being identical or different, mean respectively hydrogen, C.sub.1-6 -alkoxy, phenyl, C.sub.3-7 -cyclo-alkyl, optionally substituted C.sub.1-6 -alkyl or C.sub.1-6 -alkoxycarbonyl, and R.sup.c and R.sup.d, being identical or different, mean respectively hydrogen or C.sub.1-6 -alkyl or jointly a linkage, andR.sup.4 is hydrogen, C.sub.1-6 -alkyl or C.sub.1-6 -alkoxy-C.sub.1-6 -alkyl andR.sup.5 is hydrogen, halogen, OR.sup.6, NR.sup.7 R.sup.8 or CH R.sup.9 R.sup.10 wherein R.sup.6 means C.sub.1-6 -alkyl, C.sub.3-7 -cycloalkyl or an optionally substituted aralkyl, aryl or hetaryl residue, R.sup.7 and R.sup.8, being identical or different, represent hydrogen, C.sub.1-6 -alkyl, C.sub.3-6 -alkenyl, or jointly with the nitrogen atom a saturated heterocyclic five- or six-membered ring which optionally contains a further hetero atom, R.sup.9 means hydrogen or C.sub.1-6 -alkyl, R.sup.10 means hydrogen, C.sub.